June 18, 2015
– Novartis International AG / Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone(R) 20mg . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
– Glatopa is the first FDA-approved, substitutable generic version of Copaxone(R) 20mg, a treatment for relapsing forms of multiple sclerosis
– Sandoz has begun shipping to US customers following recent FDA approval
– Novartis and Sandoz are driving access to a full range of differentiated, high-quality MS therapeutic options, complemented by a full range of support services
Holzkirchen, Germany, June 18, 2015 – Sandoz, a Novartis company, today announced the US launch of GlatopaTM, the first generic version of Teva’s Copaxone(R) (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy.
“Sandoz, together with Momenta, is proud to announce the US market launch of a fully substitutable generic version of this important therapy, following FDA approval” said Peter Goldschmidt, President of Sandoz US.
MS is a debilitating disease affecting about half a million individuals in the US alone; only half of those diagnosed are currently treated.[1]
Glatopa, developed in collaboration with Momenta and produced entirely in the US, is indicated for the treatment of patients with relapsing forms of MS, including those who have experienced a first clinical episode and have magnetic resonance imaging (MRI) features consistent with MS.
Continue Reading – click here
~~~~~~~~~~~~~~~~~~~~
.
.
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews